Spero Therapeutics is a biotechnology business based in the US. Spero Therapeutics shares (SPRO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.19 – an increase of 0.85% over the previous week. Spero Therapeutics employs 46 staff and has a trailing 12-month revenue of around $118.5 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.19 |
|---|---|
| 52-week range | $1.01 - $1.89 |
| 50-day moving average | $1.30 |
| 200-day moving average | $1.44 |
| Wall St. target price | $5.00 |
| PE ratio | 3.6765 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $0.34 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.2 from 2024-11-20
| 1 week (2024-11-14) | -4.00% |
|---|---|
| 1 month (2024-10-21) | -6.25% |
| 3 months (2024-08-21) | -12.09% |
| 6 months (2024-05-21) | -20.53% |
| 1 year (2023-11-21) | -0.83% |
|---|---|
| 2 years (2022-11-21) | -35.48% |
| 3 years (2021-11-19) | 16.5 |
| 5 years (2019-11-21) | 11.03 |
Valuing Spero Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Spero Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Spero Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 4x. In other words, Spero Therapeutics shares trade at around 4x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Spero Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $21 million.
The EBITDA is a measure of a Spero Therapeutics's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $118.5 million |
|---|---|
| Gross profit TTM | $-42,107,000 |
| Return on assets TTM | 10.48% |
| Return on equity TTM | 25.81% |
| Profit margin | 14.74% |
| Book value | $1.49 |
| Market Capitalization | $67.6 million |
TTM: trailing 12 months
We're not expecting Spero Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Spero Therapeutics's shares have ranged in value from as little as $1.01 up to $1.89. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Spero Therapeutics's is 0.631. This would suggest that Spero Therapeutics's shares are less volatile than average (for this exchange).
Spero Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co. , Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.